Biomarin Pharma (NASDAQ 🙂 announced Wednesday the results of its first quarter. It beat analysts’ estimates and generated revenue above expectations.

Biomarin Pharma posted earnings per share $0.63 for revenue $519.4M. Investing.com polled analysts to predict EPS of $0.2024 based on $511.08M in revenue.

Biomarin Pharma shares have fallen 45.16% since the start of the year. However, they are still 14.75% below their 52-week high of $94.20 on February 10. They have been outperforming the Nasdaq by 20.17%.

After-hours trading for Biomarin Pharma shares rose by 2.10% following the release.

Biomarin Pharma’s earnings for this month are in line with other top Healthcare sectors

Biomarin Pharma reports on UnitedHealth’s April 14 earnings beat. UnitedHealth reported EPS $5.49 on revenues of $80.15B. Biomarin Pharma forecasts an EPS $5.36 on revenues of $78.73B.

J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.

Keep up to date with all the earnings reports coming soon by visiting Investing.com’s earnings calendar